Search Within

Christina T Hong

Formats
  1. Meeting Abstract (3)
  2. Journal Article (2)
Groups
  1. Department of Medicine (5)
  2. GSK Faculty (5)
  3. Genitourinary Oncology Service (5)
  4. Molecular Imaging and Therapy Service (5)
  5. Molecular Pharmacology and Chemistry Program Faculty (5)
  6. Radiology, Department of (5)

More Groups

People
  1. Dana Rathkopf (5)
  2. Howard Scher (5)
  3. Jorge Carrasquillo (5)
  4. Michael Morris (5)
  5. Neeta Pandit-Taskar (5)
  6. Steven Larson (5)

More People

Years
  1. 2013 (1)
  2. 2010 (1)
  3. 2009 (2)
  4. 2008 (1)
Publications
  1. Journal of Clinical Oncology (4)
  2. Cancer (1)
Publishers
  1. American Society of Clinical Oncology (4)
  2. Wiley Blackwell (1)

Results (5)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Repetitively dosed docetaxel and 153samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer
    Journal Article

    Autio, K. A.; Pandit-Taskar, N.; Carrasquillo, J. A.; Stephenson, R. D.; Slovin, S. F.; Rathkopf, D. E.; Hong, C.; Heller, G.; Scher, H. I.; Larson, S. M.; more...
    Cancer (2013)

    Fulltext@MSK | Save
  • Phase I pharmacokinetic (PK) and biodistribution study of radium-223 chloride in patients with castration resistant prostate cancer (CRPC) metastatic to bone
    Meeting Abstract

    Carrasquillo, J. A.; O'Donoghue, J. A.; Pandit-Taskar, N.; Rathkopf, D. E.; Aksnes, A.; Viner, C. L.; Hong, C. T.; Larson, S. M.; Scher, H. I.; Morris, M. J.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Phase I/II study of docetaxel and (153)Sm for castrate metastatic prostate cancer (CMPC): Summary of dose-escalation cohorts and first report on the expansion cohort
    Meeting Abstract

    Morris, M. J.; Pandit-Taskar, N.; Stephenson, R. D.; Hong, C.; Slovin, S. F.; Rathkopf, D.; Solit, D.; Carrasquillo, J.; Larson, S.; Scher, H. I.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer
    Journal Article

    Morris, M. J.; Pandit-Taskar, N.; Carrasquillo, J.; Divgi, C. R.; Slovin, S.; Kelly, W. K.; Rathkopf, D.; Gignac, G. A.; Solit, D.; Schwartz, L.; more...
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Phase I study of docetaxel (Tax) and (153)Sm repetitively administered for castrate metastatic prostate cancer (CMPC)
    Meeting Abstract

    Morris, M. J.; Pandit-Taskar, N.; Stephenson, R. D.; Hong, C.; Slovin, S. F.; Solit, D.; Rathkopf, D. E.; Carrasquillo, J. A.; Larson, S. M.; Scher, H. I.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save